Long-term outcome of implants placed with guided bone regeneration (GBR) using resorbable and non-resorbable membranes after 12–14 years

Key words: bone regeneration, bone substitute, bone transplantation, dental implant, graft material, human, membranes

Abstract

Aim: The aim of the present prospective study was to evaluate the long-term outcome of implants placed simultaneously with guided bone regeneration (GBR) using resorbable and non-resorbable membranes.

Materials and methods: The original study population consisted of 72 patients receiving a total of 265 implants. In all GBR-treated sites, demineralized bovine bone mineral (DBBM) was used in combination either with a collagen (CM) or an Expanded polytetrafluoroethylene (e-PTFE) membrane. A total of 112 implants was treated with CM, 41 implants were treated with e-PTFE membranes, and 112 served as a control group because implants were entirely surrounded by bone and did not need any GBR procedures. Clinical and radiographic analyses were performed after a period of 12–14 years.

Results: The median follow-up time was 12.5 years (range 12–14 years). A total of 58 patients participated in the present investigation, corresponding to 80.5% of the original study population. The cumulative implant survival rate at the follow-up examination was 93.2%. For the control group the cumulative survival rate was 94.6%, for the CM 91.9%, and for the e-PTFE 92.6%. Differences among the groups were not statistically significant. The radiographically determined marginal bone level (MBL) amounted to: control 2.36 mm (SD), CM 2.4 mm (SD), e-PTFE 2.53 mm (SD). There is no evidence (P < 0.2) that the slope of bone level over time is different for the three treatment groups.

Conclusion: It is concluded that implants placed simultaneously with GBR procedures using resorbable or non-resorbable membranes reveal a high survival rate ranging from 91.9% to 92.6%, therefore it is considered to be a safe and predictable therapy.

For implant placement in sites with insufficient bone quantity, different techniques have been established to reconstruct deficient alveolar ridges and to facilitate dental implant placement (Hammerle et al. 2002).


Among these, GBR is the most frequently used technique for bone regeneration in conjunction with or prior to implant placement. The principal idea of GBR is the use of membranes to exclude epithelial cells with a high turnover and to allow the migration of the desired cells (particularly osteoblasts) in the established wound space (Hämmerle & Jung 2003). The successful use of non-resorbable and resorbable membrane materials for GBR has been documented in the literature (Hammerle et al. 2002).

Expanded polytetrafluoroethylene membranes (e-PTFE) as barrier were regarded as standard for GBR due to its early and successful application (Dahlin et al. 1991a,b; Davarpanah et al. 1991). Despite the high predictability of bone regeneration using e-
PTFE barriers, the main disadvantages of this material are that the membrane must be removed in a second surgical intervention and that membrane exposure can cause bacterial contamination (Simion et al. 1998; Machteti 2001). Subsequently, the inflammatory reaction of the surrounding soft tissues may require early removal of the membrane. To avoid these problems the use of biodegradable materials has been investigated.

In the past 10–15 years resorbable membranes made of collagen have become the membrane of choice in many clinical situations. However, clinical long-term data using these types of membranes are scarce in dental literature.

Hence, the aim of the present prospective study was to evaluate clinical and radiological outcomes of implants placed simultaneously with GBR using resorbable and nonresorbable membranes after a period of 12–14 years.

Material and methods

Study design and original population

In the present study patients have been followed clinically and radiologically over a period of 12–14 years. All patients were treated by specialists between 1994 and 1996 at the Department of Fixed and Removable Prosthodontics and Dental Material Science at the University of Zurich, Switzerland. Patients were preoperatively informed about the treatment modalities and they gave their informed consent.

The original study population consisted of 72 patients as described in a previous study (Zitzmann et al. 2001). A subgroup with 24 of these patients was part of a former split-mouth study comparing two membranes (Zitzmann et al. 1997) randomized was carried out using Bio-Gide® and Gore-Tex® cards in sealed envelopes. One envelope was selected by each patient, and the choice on the card was applied to the defect site with the first (lowest) tooth position number using the American system. The second defect site was treated with the other membrane type.

Treatment protocol/surgical procedure

Clinical procedures

The surgical procedures are described in detail in two previous publications (Zitzmann et al. 1997, 2001). In brief, the implant site was prepared according to standard protocols for the Branemark System. The exposed portions of all implant sites were grafted with DBBM. Each site was covered with the selected membrane, which was trimmed and adapted to the shape of the individual defect so that the membrane overlapped the defect circularly by a minimum of 2 mm. The sites of implantation were primarily closed for a submerged healing. If exposure of the e-PTFE membrane occurred and signs of inflammation were present, removal of the membrane was performed. If possible, the exposed e-PTFE membrane was kept in situ for a minimum period of 6 weeks. Re-entry was performed after 4 months of healing in the mandible and 6 months in the maxilla.

Preoperative and postoperative medication

One hour prior to surgery, patients received antibiotic prophylaxis (750 mg amoxicillin). The postoperative protocol included anti-inflammatory medication according to individual requirements.

Follow-up examination

The last follow-up examination was performed at the Clinic for Fixed and Removable Prosthodontics and Dental Material Science, University of Zurich, Switzerland between the end of 2007 and 2009. Prior to the clinical and radiographic examination, a thorough medical history was obtained from each patient.

Clinical parameters

The following parameters were examined during the clinical examination:

1. Implant survival
2. Presence/absence of plaque at the implants
3. Probing pocket depths (PPD) were performed at six sites [mesio-buccal, mid-buccal, disto-buccal, disto-lingual, mid-lingual, mesio-lingual] of each implant and recorded to the nearest millimeter with the periodontal probe UNC-15 using a force of 0.2–0.3 N [examiner N.F. was calibrated in advance].
4. Bleeding on probing at six sites around the implant [BOP] (Ainamo & Bay 1975)
5. Height of the keratinized mucosa (KM) was measured with the periodontal probe UNC-15 at the buccal aspect of the implant
6. Marginal soft tissue level (MSTL) measured from the top of the abutment (abutment-crown junction) to the soft tissue margin. Positive values described the abutment margin located in a supracrestal position, while negative values represented a submucosal position of the abutment-crown junction.

Radiographic analysis

For the evaluation of the marginal bone level, intraoral radiographs were taken using the long-cone paralleling technique with the central beam directed to the alveolar crest [Hawe X-ray film holder; Kerrhawe SA, Bioggio, Göteborg, Sweden], 8 Biomed 3i (Biomet 3i, Palm Beach Gardens, FL, USA), one IMZ [Friatec® AG, Mannheim, Germany]. Different implant lengths and diameters were used, with implant lengths varying between 6 and 20 mm, and diameters from 3.75 to 5 mm.

All test sites were treated with demineralized bovine bone mineral [DBBM] [Bio-Oss®, Geistlich AG, Wolhusen, Switzerland] as a membrane supporting material and covered with either collagen membranes [CM] [Bio-Gide®, Geistlich AG, Wolhusen, Switzerland] or e-PTFE membranes [Gore-Tex®, W.L. Gore/Implant Innovations, West Palm Beach, FL, USA]. A total of 112 implants was treated with CM, in 41 implants e-PTFE membranes were applied, and 112 implants served as a control group because implants were entirely surrounded by bone and did not need any GBR procedures.

In the subgroup with 24 patients that was part of a former split-mouth study comparing two membranes (Zitzmann et al. 1997) randomization was carried out using Bio-Gide® and Gore-Tex® cards in sealed envelopes. One envelope was selected by each patient, and the choice on the card was applied to the defect site with the first (lowest) tooth position number using the American system. The second defect site was treated with the other membrane type.
data set. It takes into account that data from one subject are more similar to each other than between subjects (i.e., the within-subject correlation), and that the within-subject differences have smaller variances compared to between-subject differences.

From the linear model, predictions for a follow-up time of 12 years and their between-treatment pairwise differences were computed, and confidence intervals were given.

For the analysis of the implant survival [time to implant loss], the full [intention-to-treat (ITT) data set was used; for dropouts, the last known implant survival time was censored.

The ITT subset consists of all data collected in the study published in 2001 [Zitzmann et al. 2001] and the present study, and includes patients who were early losses of dropouts. The full subset was used for Cox regression analysis of implant survival only, and applied the last date recorded for implant function as the possibly censored survival time. This ITT subset comprised 72 patients with 265 implants.

Results

Follow-up outcomes

Study population and drop out
A total of 58 patients with 222 implants participated in the present study, which represents 80.5% of the original study population consisting of 72 patients. A total of 45 patients were women and 13 were men. The median age at the time of re-examination was 67.5 years (range 32–87 years). Fourteen patients could not be examined. Six of these 14 patients died and 8 patients could not be reached for re-examination because of geographic reasons or severe illness. One of the subjects [age 88] who was not re-examined because of illness confirmed by phone that the implant reconstruction was in place without any problems. All patients were examined by one examiner, except six subjects who went to their private dentists and gave their approval to transfer clinical data and radiographs. One patient refused to take current radiographs at the examination but the dentist confirmed that all implants were stable and without clinical symptoms or radiologic diagnoses. Therefore, a total of 222 implants could be reassessed after a median observation period of 12.5 years [range 12–14 years].

From the 43 implants in 14 patients that could not be evaluated, 21 were treated with CM, 3 with e-PTFE, and 19 were part of the control group.

The distribution of the implant location in the upper and the lower jaw was very homogeneous [Table 1]. The majority of implants was restored with fixed dental prostheses. The proportions of the type of restoration were different in each of the three treatment groups and are shown in Table 2.

Health questionnaire

Due to the increased age of the population [median age 67.5 years] a high incidence of different diseases was reported. These include three patients with diabetes mellitus, one patient with breast cancer, three patients with cerebral apoplexy, one with a heart attack, and one with Alzheimer’s disease. Patient’s history revealed that seven individuals smoked and seven did not answer this question.

Personal questionnaire

The evaluation of patients’ satisfaction with the implants and the restoration was 10 on a scale of 10 for 76% implants; for 9% of the implants, satisfaction was 0/10.

Clinical examinations

Implant survival

The cumulative implant survival rate at the 12.5 years follow-up examination was 93.2% with 18 implants lost out of 265.

Table 1. Distribution of implant location n (%)

<table>
<thead>
<tr>
<th>Location</th>
<th>Front</th>
<th>Premolar</th>
<th>Molar</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maxilla</td>
<td>112</td>
<td>44</td>
<td>56</td>
</tr>
<tr>
<td>Mandible</td>
<td>110</td>
<td>13</td>
<td>40</td>
</tr>
<tr>
<td>Total</td>
<td>222</td>
<td>57</td>
<td>96</td>
</tr>
</tbody>
</table>

Table 2. Distribution of different types of restorations in the treatment groups: n (%)

<table>
<thead>
<tr>
<th>Type of restoration</th>
<th>CM (n = 91)</th>
<th>e-PTFE (n = 38)</th>
<th>Control (n = 93)</th>
<th>Total (n = 222)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fixed single-tooth</td>
<td>9 (9.9%)</td>
<td>2 (5.3%)</td>
<td>7 (7.5%)</td>
<td>18 (8.1%)</td>
</tr>
<tr>
<td>Fixed &gt; 1 unit</td>
<td>67 (73.6%)</td>
<td>27 (71.0%)</td>
<td>71 (76.3%)</td>
<td>165 (74.3%)</td>
</tr>
<tr>
<td>Removable Overdentine</td>
<td>13 (14.3%)</td>
<td>9 (23.7%)</td>
<td>15 (16.1%)</td>
<td>37 (16.6%)</td>
</tr>
<tr>
<td>Unloaded (sleeper)</td>
<td>2 (2.2%)</td>
<td>–</td>
<td>–</td>
<td>2 (0.9%)</td>
</tr>
</tbody>
</table>
In the control group 6 implants out of 112 were lost and the cumulative survival rate was 94.6%. In the CM group 9 implants of 112 were lost with a survival rate of 91.9%. In the e-PTFE group 3 implants of 41 were lost, the survival rate was 94.6%. In the CM group 9 implants of 112 were lost and the cumulative survival rate was 92.6% (Table 3 and Fig. 1). Statistically there is no evidence for differences in implant survival among the three treatment groups.

### Probing pocket depth

In the original study probing pocket depth was not measured. The present study revealed that the probing depth in the maxilla and mandible were 0.7 mm higher than that in the mandible ($P = 0.0039$, Table 4). However, there is no evidence that probing depth was different among the three treatment groups (Table 5).

### Height of the keratinized mucosa

The mean height of keratinized mucosa on the buccal aspect was higher in the maxilla than in the mandible. Estimated values of keratinization at 12.5 years follow-up are given in Table 6.

### Marginal soft tissue level

Forty-nine percent of all crown margins at the mid-buccal aspect were not visible after 12.5 years and were located either in a submucosal position (26%) or at the abutment-crown junction (23%) (Figs 2–4). In contrast, 51% of the crown margins were visible and the crown margins were located in a supragingival position (Figs 5–7).

The estimated MSTL at the 12.5 years follow-up for the e-PTFE group was significantly closer to zero compared to the control group by $-0.32$ mm ($P = 0.01$), for the CM group it is marginally closer to zero compared to the control group by $-0.17$ mm ($P = 0.06$). For all treatments the regression is estimated to progress at $0.068$ mm/year, with a 95%-confidence interval of $0.047–0.089$ mm/year (Table 7).

### Radiological examinations

The radiographic evaluation demonstrated that all but two implants were radiographically integrated, indicated by a direct contact between the bone and the implant. Two implants revealed an almost complete bone loss and were considered as implant failures (Fig. 8). For statistical analysis these two implants were counted as implant losses and are included in Table 3 and Fig. 1.

The mean distance of the first bone-to-implant contact to the implant-abutment junction amounted to 2.36 mm for the control group, 2.4 mm for the CM group and to 2.53 mm for the e-PTFE group (Correction added after online publication 30 November 2012: the mean distance of the first bone-to-implant contact to the implant-abutment junction was corrected to 2.36 mm for the control group, 2.4 mm for the CM group and to 2.53 mm for the e-PTFE group) (Table 8). There was no evidence that the slope of the bone level over time differed among the three treatment groups ($P < 0.2$) (Table 9). The average change in bone level over time was 0.081 mm/year, with a 95% confidence interval of 0.072–0.09 mm/year (Fig. 9).

The correlation between the marginal bone level and the MSTL is shown in Fig. 10. With greater distances from the bone-to-implant contact to the implant-abutment junction, higher MSTLs were found.

### Discussion

The present prospective study evaluated the clinical and radiographic outcomes of implants placed simultaneously with GBR using resorbable and non-resorbable membranes after a period of 12.5 years. Similar survival rates for implants placed with or without bone augmentation were demonstrated, and results did not depend on the membrane material used. With 18 implant
losses of 265 (7%), all treatment modalities revealed a generally low number of implant failures.

A lot of effort was given to recall as much patients as possible for the present long-term study even if they had not been in regular maintenance care for the last 8 years. Therefore, 80.5% of the entire study population could be reassessed. This is comparable to a recent long-term study documenting a value of 84.2% of recalled patients after 17–19 years (Bergenblock et al. 2010). Another clinical long-term investigation included 72% of the original study group after 10–16 years (Simonis et al. 2010).

One major interest in longitudinal studies is the survival rate. The present study showed an overall survival rate of 93% after 12.5 years. This is higher compared to a recent long-term study showing a survival rate of 89.3% after 10 years and a cumulative survival rate up to 16 years of 82.9% (Simonis et al. 2010). In contrast to the aforementioned studies, the present investigation included implants placed simultaneously with bone augmentation procedures using two different types of membranes. To our knowledge, there are presently no other long-term studies evaluating implants placed in regenerated bone using different types of membranes.

Two systematic reviews dealt with survival rates of implants placed in regenerated bone (Hammerle et al. 2002; Donos et al. 2008). In the more recent review, the implant survival rate at the augmented sites varied irrespective of the procedure from 91.7% to 100% and from 93.2% to 100% at the control sites for a period between 12 and 59.1 months (Donos et al. 2008). In the review from 2002, the survival rate of implants placed into sites with augmented bone using barrier membranes varied between 79% and 100% with the majority of studies indicating more than 90% survival after at least 1 year of function (Hammerle et al. 2002). In this systematic review three studies were included reporting on 5-year data of implants placed in regenerated bone (Buser et al. 1996; Becker et al. 1999, Zitzmann et al. 2001). Survival rates were 79.4% for implants with dehiscence/fenestration defects treated with e-PTFE membranes and 93.9% for implants in extraction sites treated with e-PTFE membranes.
Becker et al. 1999) and 100% for implants treated with e-PTFE membranes (Buser et al. 1996). In the third study, the survival rate was 92.6% for implants treated with e-PTFE membranes and 95.4% for implants treated with collagen membrane (Zitzmann et al. 2001). The latter included the same patient population as the present study. Based on all these clinical data the present study revealed a quite high implant survival rate after a mean observation period of 12.5 years.

Another important parameter of longitudinal studies is the radiographic change in marginal bone level over time. The present study revealed radiographic bone changes from 6 months until the follow-up of at least 12 years. It seems to be confirmed that marginal bone level changes take place particularly within the first 12 months after implant placement and functional loading. Thereafter, the bone level changes reached a plateau revealing minimal bone loss over time (Zitzmann et al. 2001). The radiographic examination in the present study showed that the average bone loss over the mean observation period of 12.5 years was 0.081 mm/year, with a 95% confidence interval of 0.072–0.09 mm/year. The estimated radiological bone level after 12.5 years resulted in 2.36 mm for the control group, 2.4 mm for the CM and 2.53 mm for the e-PTFE group. Keeping the average bone loss of 0.081 mm/year in mind, the marginal bone level in the present investigation seems to be comparable to studies with shorter observation periods. A recently published retrospective cross-sectional study reported about marginal bone levels of 1.73 mm for the group without GBR procedures and 1.83 mm for the test group with bone augmentation after only 5 years (Benic et al. 2009). Another clinical study measured a mean marginal bone level at implants treated with GBR of 2.05 mm after 5 years (Blanco et al. 2005).

Limited data are available on studies comparing the clinical and radiographic outcome of implants placed with simultaneous GBR with implants placed in pristine bone. Two systematic reviews and one clinical study reported no difference in terms of radiographic marginal bone level between implants placed in pristine bone and

| Table 7. Estimated values of MSTL 12 years after implant placement with standard errors and 95%-confidence intervals |
|-----------------|----------------|----------------|----------------|
| MSTL            | Estimate       | SE             | Lower CI       | Upper CI      |
| Control.12      | 0.70           | 0.11           | 0.48           | 0.93          |
| CM.12           | 0.54           | 0.11           | 0.32           | 0.75          |
| e-PTFE.12       | 0.39           | 0.14           | 0.11           | 0.67          |
implants combined with bone regeneration procedures (Hammerle et al. 2002; Donos et al. 2008; Benic et al. 2009). In the present study the sites treated with e-PTFE membrane showed slightly more bone loss compared to the other two groups. This might be explained by the fact that the sites treated with e-PTFE revealed more soft tissue complications and membrane exposures within the early healing phase (Zitzmann et al. 1997).

Several previous clinical studies reported a reduced amount of bone regeneration in sites demonstrating early membrane exposure and removal compared to sites with uneventful healing (Simion et al. 1994; Becker et al. 1999, Moses et al. 2005).

The MSTL has been assessed after 6 months until the final examination at 12.5 years in the present study. It would be of clinical importance to predict bone loss by clinical measurements of the MSTL or the height of keratinized mucosa. The statistical analysis revealed a significant correlation between the marginal bone level and MSTL ($P = 8.4 \times 10^{-5}$). However, these results have to be interpreted with caution. Even if the predictive effect is present, the correlation between bone level and MSTL is low with $r = 0.32$. In contrast, the statistics shows no evidence that the height of keratinized mucosa is a predictor for bone loss. In general, one of the intentions of performing GBR procedures at an implant site is to maintain the MSTL at the buccal aspect. The present study revealed no difference between MSTL at the control vs. CM or ePTFE sites. Hence, it can be speculated that the augmented bone, irrespective of the preoperative defect morphology, was able to support the soft tissue in a similar way as the native bone. However, it is important to mention that 51% of the crown margins were visible and were located in a supramucosal position after a mean follow-up time of 12.5 years. The data did not demonstrate any difference between the groups revealing a similar behavior of sites with GBR and without GBR in terms of MSTLs. Statistically, there is no evi-

**Table 8.** Estimated values of bone level 12 years after operation, with standard errors and 95%-confidence intervals

<table>
<thead>
<tr>
<th>Bone level</th>
<th>Estimate</th>
<th>SE</th>
<th>Lower.Cl</th>
<th>Upper.Cl</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control.12</td>
<td>2.36</td>
<td>0.08</td>
<td>2.20</td>
<td>2.53</td>
</tr>
<tr>
<td>CM.12</td>
<td>2.40</td>
<td>0.08</td>
<td>2.24</td>
<td>2.56</td>
</tr>
<tr>
<td>e-PTFE.12</td>
<td>2.53</td>
<td>0.11</td>
<td>2.30</td>
<td>2.75</td>
</tr>
</tbody>
</table>

**Table 9.** Estimated pairwise differences of bone loss 12 years after implant placement with standard errors and 95%-confidence intervals of the differences

| Bone level diff | Estimate | SE  | Lower.Cl | Upper.Cl | Pr(|t|) |
|-----------------|----------|-----|----------|----------|-------|
| CM - Control    | 0.04     | 0.08| -0.12    | 0.20     | 0.63  |
| e-PTFE - Control| 0.17     | 0.11| -0.05    | 0.39     | 0.13  |
| CM - e-PTFE     | -0.13    | 0.11| -0.35    | 0.09     | 0.24  |

Fig. 8. Most significant implant and prosthetic failure within the entire study population (control group): clinical situation and radiograph.

Fig. 9. Dot plot of bone loss data by treatment. For display only, data were randomly jittered to better separate overlapping data points. Standard errors indicated by shaded bands are approximate and must not be used for statistical interference.

© 2012 John Wiley & Sons A/S

Jung et al. Long-term outcome of GBR after 12–14 years
dence that patient satisfaction and MStL are correlated.

It is concluded that implants placed simultaneously with GBR procedures using resorbable or non-resorbable membranes reveal a high survival rate ranging from 91.9% to 92.6%. There was no statistical significant difference compared to implants placed in pristine bone without GBR procedures demonstrating an implant survival rate of 94.6% after 12.5 years of observation. Clinically and radiologically there was no difference between resorbable CM or non-resorbable e-PTFE membranes, considering these procedures as safe and predictable therapies over a long-term follow-up time of 12–14 years.

Acknowledgements: The authors express their special thanks to Dr. Dieter Menne (Menne Biomed Consulting, D-72074 Tübingen) for performing the statistical analysis and providing continuous expertise and support throughout the manuscript preparation. This study has been supported and founded by the Clinic for Fixed and Removable Prosthodontics, University of Zürich, Switzerland.

References


Fig 10. Scatter plot of bone loss vs. marginal soft tissue level and estimated prediction line. The correlation between the variables was low ($r = –0.32$).


Copyright of Clinical Oral Implants Research is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use.